Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Coagulation abnormalities of sickle cell disease: Relationship with clinical outcomes and the effect of disease modifying therapies
source: Blood Reviews
year: 2016
authors: Noubouossie D, Key NS, Ataga KI
summary/abstract:Sickle cell disease (SCD) is a hypercoagulable state. Patients exhibit increased platelet activation, high plasma levels of markers of thrombin generation, depletion of natural anticoagulant proteins, abnormal activation of the fibrinolytic system, and increased tissue factor expression, even in the non-crisis “steady state.” Furthermore, SCD is characterized by an increased risk of thrombotic complications. The pathogenesis of coagulation activation in SCD appears to be multi-factorial, with contributions from ischemia-reperfusion injury and inflammation, hemolysis and nitric oxide deficiency, and increased sickle RBC phosphatidylserine expression. Recent studies in animal models suggest that activation of coagulation may contribute to the pathogenesis of SCD, but the data on the contribution of coagulation and platelet activation to SCD-related complications in humans are limited. Clinical trials of new generations of anticoagulants and antiplatelet agents, using a variety of clinical endpoints are warranted.
organization: University of North CarolinaDOI: 10.1016/j.blre.2015.12.003
read more full text
Related Content
-
Changes in transcranial doppler flow velocities in children with sickle cell disease: The impact of hydroxyurea ther...Background and Objectives: Hydroxyurea ...
-
Genetic Treatments for Sickle CellFor decades physicians have known that a...
-
Isaac Singleton: Sickle Cell Freehttps://www.youtube.com/watch?v=a5mMgnuz...
-
Today’s Faces of Sickle Cell Disease: Tesha SamuelsTesha Samuels was diagnosed with SCD at ...
-
Sleep and Your HealthAs life gets more hectic, it is all too ...
-
Sickle cell advocate wins fight for high-dose opioidsGeorge H. Carter appears to have won h...
-
Global Blood Therapeutics (GBT) announces upcoming data presentations supporting Voxelotor SCD programGlobal Blood Therapeutics, Inc. (GBT) ...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.